Tysabri only has priority review status, not accelerated. Gleevec is a cancer drug and is a life threatning disease. I am not sure MS is considered a life threatning disease, but I am sure it is considered an unmet need disease that is under-served.
Priority review only applies to the NDA/BLA filing. Not the clinical trial design.